GlaxoSmithKline and Isis Pharmaceuticals have entered a strategic alliance that will apply Isis’ antisense drug discovery platform to develop new therapeutics against targets for rare and infectious diseases. Isis will receive a $35 million upfront payment from GSK and is eligible to receive as much as $20 million in milestones per program up to Phase II proof-of-concept. The agreement covers as many as six programs. GSK will have the option to license compounds and will be responsible for al...